Cargando…

Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms

Introduction: Most conventional drug delivery systems are not acceptable for pediatric patients as they differ in their developmental status and dosing requirements from other subsets of the population. Technology platforms are required to aid the development of age-appropriate medicines to maximize...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Felipe L, Ernest, Terry B, Tuleu, Catherine, Gul, Mine Orlu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673516/
https://www.ncbi.nlm.nih.gov/pubmed/26165848
http://dx.doi.org/10.1517/17425247.2015.1060218
_version_ 1782404754411880448
author Lopez, Felipe L
Ernest, Terry B
Tuleu, Catherine
Gul, Mine Orlu
author_facet Lopez, Felipe L
Ernest, Terry B
Tuleu, Catherine
Gul, Mine Orlu
author_sort Lopez, Felipe L
collection PubMed
description Introduction: Most conventional drug delivery systems are not acceptable for pediatric patients as they differ in their developmental status and dosing requirements from other subsets of the population. Technology platforms are required to aid the development of age-appropriate medicines to maximize patient acceptability while maintaining safety, efficacy, accessibility and affordability. Areas covered: The current approaches and novel developments in the field of age-appropriate drug delivery for pediatric patients are critically discussed including patient-centric formulations, administration devices and packaging systems. Expert opinion: Despite the incentives provided by recent regulatory modifications and the efforts of formulation scientists, there is still a need for implementation of pharmaceutical technologies that enable the manufacture of licensed age-appropriate formulations. Harmonization of endeavors from regulators, industry and academia by sharing learning associated with data obtained from pediatric investigation plans, product development pathways and scientific projects would be the way forward to speed up bench-to-market age appropriate formulation development. A collaborative approach will benefit not only pediatrics, but other patient populations such as geriatrics would also benefit from an accelerated patient-centric approach to drug delivery.
format Online
Article
Text
id pubmed-4673516
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Informa Healthcare
record_format MEDLINE/PubMed
spelling pubmed-46735162015-12-15 Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms Lopez, Felipe L Ernest, Terry B Tuleu, Catherine Gul, Mine Orlu Expert Opin Drug Deliv Reviews Introduction: Most conventional drug delivery systems are not acceptable for pediatric patients as they differ in their developmental status and dosing requirements from other subsets of the population. Technology platforms are required to aid the development of age-appropriate medicines to maximize patient acceptability while maintaining safety, efficacy, accessibility and affordability. Areas covered: The current approaches and novel developments in the field of age-appropriate drug delivery for pediatric patients are critically discussed including patient-centric formulations, administration devices and packaging systems. Expert opinion: Despite the incentives provided by recent regulatory modifications and the efforts of formulation scientists, there is still a need for implementation of pharmaceutical technologies that enable the manufacture of licensed age-appropriate formulations. Harmonization of endeavors from regulators, industry and academia by sharing learning associated with data obtained from pediatric investigation plans, product development pathways and scientific projects would be the way forward to speed up bench-to-market age appropriate formulation development. A collaborative approach will benefit not only pediatrics, but other patient populations such as geriatrics would also benefit from an accelerated patient-centric approach to drug delivery. Informa Healthcare 2015-11-02 2015-07-13 /pmc/articles/PMC4673516/ /pubmed/26165848 http://dx.doi.org/10.1517/17425247.2015.1060218 Text en © 2015 The Author(s). Published by Taylor & Francis. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Lopez, Felipe L
Ernest, Terry B
Tuleu, Catherine
Gul, Mine Orlu
Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms
title Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms
title_full Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms
title_fullStr Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms
title_full_unstemmed Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms
title_short Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms
title_sort formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673516/
https://www.ncbi.nlm.nih.gov/pubmed/26165848
http://dx.doi.org/10.1517/17425247.2015.1060218
work_keys_str_mv AT lopezfelipel formulationapproachestopediatricoraldrugdeliverybenefitsandlimitationsofcurrentplatforms
AT ernestterryb formulationapproachestopediatricoraldrugdeliverybenefitsandlimitationsofcurrentplatforms
AT tuleucatherine formulationapproachestopediatricoraldrugdeliverybenefitsandlimitationsofcurrentplatforms
AT gulmineorlu formulationapproachestopediatricoraldrugdeliverybenefitsandlimitationsofcurrentplatforms